{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:38:11Z","timestamp":1793147891759,"version":"4.5.0"},"reference-count":45,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2026,4,16]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      We explored the efficacy of AS01\n                      <jats:sub>E<\/jats:sub>\n                      -adjuvanted respiratory syncytial virus prefusion F protein-based vaccine (adjuvanted RSVPreF3) in subpopulations of participants with underlying medical conditions in the multi-country, phase 3 AReSVi-006 trial (conducted between May 2021 and May 2024).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Medically stable \u226560-year-olds were 1:1-randomised to receive one adjuvanted RSVPreF3 or placebo dose pre-RSV season 1. In exploratory\n                      <jats:italic>post hoc<\/jats:italic>\n                      analyses in subgroups of participants with underlying conditions (including COPD, asthma, diabetes and obesity (body mass index \u226530\u2005kg\u00b7m\n                      <jats:sup>\u22122<\/jats:sup>\n                      )), we evaluated efficacy of one vaccine dose against RSV-related lower respiratory tract disease (RSV-LRTD), RSV-related acute respiratory illness (RSV-ARI) and RSV-ARI-related complications (\n                      <jats:italic>e.g.<\/jats:italic>\n                      , pneumonia, COPD\/asthma exacerbation and cardiovascular events). We also evaluated (\n                      <jats:italic>post hoc<\/jats:italic>\n                      ) RSV-ARI-related systemic corticosteroid and antibiotics use in participants with COPD or asthma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The efficacy analyses comprised 12\u2009468 vaccine and 12\u2009498 placebo recipients. Efficacy against RSV-LRTD over three RSV seasons was similar among participants with COPD (75.1%, 95% CI: 40.2\u201391.4), asthma (65.8%, 31.0\u201384.7), diabetes (69.8%, 37.5\u201387.1) and obesity (74.1%, 56.4\u201385.5) as in the overall study population (62.9%, 97.5% CI: 46.7\u201374.8). Efficacy was also observed against RSV-ARI in these subgroups. Efficacy against RSV-ARI-related complications was 74.4% (95% CI: 11.2\u201395.2) in participants with COPD and 60.8% (\u22129.9\u201388.7) in those with asthma. Among participants with COPD, 15.4% (1.9\u201345.4) of RSV-ARI episodes in vaccine\n                      <jats:italic>versus<\/jats:italic>\n                      22.4% (12.5\u201335.3) in placebo recipients were treated with systemic corticosteroids, and 46.2% (19.2\u201374.9)\n                      <jats:italic>versus<\/jats:italic>\n                      56.9% (43.2\u201369.8) with antibiotics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Post hoc<\/jats:italic>\n                      analyses of the AReSVi-006 trial suggest that adjuvanted RSVPreF3 may help prevent RSV-ARI, RSV-LRTD and RSV-related complications in medically stable older adults with underlying medical conditions like COPD and asthma.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.00418-2026","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:50:17Z","timestamp":1781797817000},"page":"00418-2026","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Adjuvanted RSVPreF3 vaccine impact over three respiratory syncytial virus seasons in older adults with comorbidities"],"prefix":"10.1183","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6924-4500","authenticated-orcid":false,"given":"Alberto","family":"Papi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-4406","authenticated-orcid":false,"given":"David M.G.","family":"Halpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Ison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tino F.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Gun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Antonelli Incalzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Fissette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stebin","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shady","family":"Kotb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Mar\u00e9chal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Hulstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Van der Wielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"2026092101450597000_12.5.00418-2026.1","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1093\/cid\/ciaa730","article-title":"Respiratory syncytial virus-associated hospitalizations among adults with chronic medical conditions","volume":"73","author":"Prasad","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026092101450597000_12.5.00418-2026.2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab595"},{"key":"2026092101450597000_12.5.00418-2026.3","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad513"},{"key":"2026092101450597000_12.5.00418-2026.4","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad510"},{"key":"2026092101450597000_12.5.00418-2026.5","doi-asserted-by":"crossref","first-page":"2400364","DOI":"10.2807\/1560-7917.ES.2025.30.10.2400364","article-title":"Hospitalisation due to respiratory syncytial virus in a population-based cohort of older adults in Spain, 2016\/17 to 2019\/20","volume":"30","author":"Vera-Punzano","year":"2025","journal-title":"Euro Surveill"},{"key":"2026092101450597000_12.5.00418-2026.6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11882-025-01194-w","article-title":"Burden of respiratory syncytial virus disease in adults with asthma and chronic obstructive pulmonary disease: a systematic literature review","volume":"25","author":"Penders","year":"2025","journal-title":"Curr Allergy Asthma Rep"},{"key":"2026092101450597000_12.5.00418-2026.7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pcad.2025.06.010","article-title":"Burden and severity of respiratory syncytial virus infection in adults with cardiovascular diseases: a systematic literature review","volume":"92","author":"Penders","year":"2025","journal-title":"Prog Cardiovasc Dis"},{"key":"2026092101450597000_12.5.00418-2026.8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy991"},{"key":"2026092101450597000_12.5.00418-2026.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043951"},{"key":"2026092101450597000_12.5.00418-2026.10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit471"},{"key":"2026092101450597000_12.5.00418-2026.11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1164\/rccm.202308-1320OC","article-title":"Respiratory syncytial virus-related community chronic obstructive pulmonary disease exacerbations and novel diagnostics: a binational prospective cohort study","volume":"210","author":"Wiseman","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026092101450597000_12.5.00418-2026.12","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jamainternmed.2024.0212","article-title":"Acute cardiac events in hospitalized older adults with respiratory syncytial virus infection","volume":"184","author":"Woodruff","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2026092101450597000_12.5.00418-2026.13","unstructured":"Global Initiative for Chronic Obstructive Lung Disease . Global strategy for prevention, diagnosis and management of COPD: 2025 report. Date last: accessed 30 June 2025. https:\/\/goldcopd.org\/wp-content\/uploads\/2024\/11\/GOLD-2025-Report-v1.0-15Nov2024_WMV.pdf"},{"key":"2026092101450597000_12.5.00418-2026.14","unstructured":"Global Initiative for Asthma . Global strategy for asthma management and prevention (2025 update). Date last accessed: 30 June 2025. https:\/\/ginasthma.org\/2025-gina-strategy-report\/"},{"key":"2026092101450597000_12.5.00418-2026.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2008.03157.x"},{"key":"2026092101450597000_12.5.00418-2026.16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaci.2025.10.023","article-title":"A promise fulfilled: updates on respiratory syncytial virus vaccines and monoclonal antibodies","volume":"157","author":"Murray","year":"2026","journal-title":"J Allergy Clin Immunol"},{"key":"2026092101450597000_12.5.00418-2026.17","unstructured":"European Medicines Agency . Arexvy. Date last accessed: 28 April 2025. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/arexvy."},{"key":"2026092101450597000_12.5.00418-2026.18","unstructured":"U.S. Food and Drug Administration . Arexvy. Date last accessed: 28 April 2025. www.fda.gov\/vaccines-blood-biologics\/arexvy"},{"key":"2026092101450597000_12.5.00418-2026.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209604"},{"key":"2026092101450597000_12.5.00418-2026.20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae010"},{"key":"2026092101450597000_12.5.00418-2026.21","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(25)00048-7"},{"key":"2026092101450597000_12.5.00418-2026.22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/cid\/ciad471","article-title":"Respiratory syncytial virus prefusion F protein vaccine is efficacious in older adults with underlying medical conditions","volume":"78","author":"Feldman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026092101450597000_12.5.00418-2026.23","doi-asserted-by":"crossref","first-page":"e258322","DOI":"10.1001\/jamanetworkopen.2025.8322","article-title":"Effectiveness and safety of respiratory syncytial virus vaccine for US adults aged 60 years or older","volume":"8","author":"Fry","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026092101450597000_12.5.00418-2026.24","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jama.2024.15775","article-title":"RSV vaccine effectiveness against hospitalization among US adults 60 years and older","volume":"332","author":"Surie","year":"2024","journal-title":"JAMA"},{"key":"2026092101450597000_12.5.00418-2026.25","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(24)01738-0","article-title":"Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60\u2005years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis","volume":"404","author":"Payne","year":"2024","journal-title":"Lancet"},{"key":"2026092101450597000_12.5.00418-2026.26","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1001\/jama.2025.15896","article-title":"RSV vaccine effectiveness against hospitalization among US adults aged 60 years or older during 2 seasons","volume":"334","author":"Surie","year":"2025","journal-title":"JAMA"},{"key":"2026092101450597000_12.5.00418-2026.27","doi-asserted-by":"crossref","first-page":"e13236","DOI":"10.1111\/irv.13236","article-title":"The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults \u226560\u2009years of age","volume":"18","author":"Curran","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"key":"2026092101450597000_12.5.00418-2026.28","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7240a1"},{"key":"2026092101450597000_12.5.00418-2026.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106020"},{"key":"2026092101450597000_12.5.00418-2026.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2014.06.025"},{"key":"2026092101450597000_12.5.00418-2026.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61382-8"},{"key":"2026092101450597000_12.5.00418-2026.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33311-1"},{"key":"2026092101450597000_12.5.00418-2026.33","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202406-1254CI"},{"key":"2026092101450597000_12.5.00418-2026.34","doi-asserted-by":"crossref","unstructured":"Singer D , Steffens A , La E , et al. Effectiveness of adjuvanted RSVPreF3 vaccine in preventing major adverse cardiovascular events, severe asthma exacerbations, and severe COPD exacerbations among US adults aged 60\u2005years and older. Presented at ReSViNET conference, Rome, Italy, 17\u201320 February 2026.","DOI":"10.1016\/j.chest.2026.06.059"},{"key":"2026092101450597000_12.5.00418-2026.35","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.resinv.2024.03.009","article-title":"Treatment with systemic corticosteroid versus placebo for exacerbations of COPD: a systematic review and meta-analysis","volume":"62","author":"Koarai","year":"2024","journal-title":"Respir Investig"},{"key":"2026092101450597000_12.5.00418-2026.36","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201904-0903SO"},{"key":"2026092101450597000_12.5.00418-2026.37","doi-asserted-by":"publisher","DOI":"10.7326\/M19-3007"},{"key":"2026092101450597000_12.5.00418-2026.38","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S176026"},{"key":"2026092101450597000_12.5.00418-2026.39","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab062"},{"key":"2026092101450597000_12.5.00418-2026.40","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13043"},{"key":"2026092101450597000_12.5.00418-2026.41","doi-asserted-by":"crossref","first-page":"696","DOI":"10.15585\/mmwr.mm7332e1","article-title":"Use of respiratory syncytial virus vaccines in adults aged \u226560 years: updated recommendations of the advisory committee on immunization practices \u2013 United States, 2024","volume":"73","author":"Britton","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026092101450597000_12.5.00418-2026.42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40121-024-01081-3","article-title":"A narrative review of key risk factors for severe illness following SARS-CoV-2, influenza virus, and respiratory syncytial virus infection","volume":"14","author":"Branche","year":"2025","journal-title":"Infect Dis Ther"},{"key":"2026092101450597000_12.5.00418-2026.43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/v14010025","article-title":"Pandemics of the 21st century: the risk factor for obese people","volume":"14","author":"Hanckov\u00e1","year":"2021","journal-title":"Viruses"},{"key":"2026092101450597000_12.5.00418-2026.44","unstructured":"Fonseca MJ , Bratkovi\u0107 S , \u00c7olak Y , et al. Real-world evidence of the adjuvanted-RSVPreF3 vaccine's uptake and effectiveness among chronic obstructive pulmonary disease patients in Denmark: a nationwide cohort study. Presented at ReSViNET conference, Rome, Italy, 17\u201320 February 2026."},{"key":"2026092101450597000_12.5.00418-2026.45","doi-asserted-by":"crossref","unstructured":"Singer D , Steffens A , La E , et al. Adjuvanted RSVPreF3 vaccine effectiveness against RSV-related hospitalization among US adults aged 60\u2005years and older. Presented at ReSViNET conference, Rome, Italy, 17\u201320 February 2026.","DOI":"10.1016\/j.anzjph.2026.100356"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00418-2026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:45:23Z","timestamp":1789980323000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00418-2026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,21]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1183\/23120541.00418-2026"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00418-2026","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]}}}